Synonyms: compound 68 [WO2010002845A2] | HMPL-813 | HMPL813
Compound class:
Synthetic organic
Comment: Epitinib (HMPL-813) is a selective EGFR tyrosine kinase inhibitor that is under investigation for potential to treat solid tumours in China. Epitinib appears to be a 'pseudo' INN. As of July 2021 there had been no submission to the WHO for the INN. The chemical structure is claimed in patent WO2010002845A2 [1].
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
4-ethyl-N-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide |
Synonyms ![]() |
compound 68 [WO2010002845A2] | HMPL-813 | HMPL813 |
Database Links ![]() |
|
GtoPdb PubChem SID | 442878642 |
PubChem CID | 59142777 |
Search Google for chemical match using the InChIKey | DQAZPZIYEOGZAF-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | DQAZPZIYEOGZAF |
UniChem Compound Search for chemical match using the InChIKey | DQAZPZIYEOGZAF-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | DQAZPZIYEOGZAF-UHFFFAOYSA-N |